- Home
- IDR vs XOMA Comparison
IDR vs XOMA Comparison
Compare IDR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- XOMA
- Stock Information
- Founded
- IDR 1996
- XOMA 1981
- Country
- IDR United States
- XOMA United States
- Employees
- IDR N/A
- XOMA N/A
- Industry
- IDR Precious Metals
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- XOMA Health Care
- Exchange
- IDR Nasdaq
- XOMA Nasdaq
- Market Cap
- IDR 378.0M
- XOMA 330.2M
- IPO Year
- IDR N/A
- XOMA N/A
- Fundamental
- Price
- IDR $25.51
- XOMA $31.37
- Analyst Decision
- IDR Strong Buy
- XOMA Strong Buy
- Analyst Count
- IDR 1
- XOMA 2
- Target Price
- IDR $17.50
- XOMA $69.50
- AVG Volume (30 Days)
- IDR 475.0K
- XOMA 33.4K
- Earning Date
- IDR 08-07-2025
- XOMA 08-13-2025
- Dividend Yield
- IDR N/A
- XOMA N/A
- EPS Growth
- IDR 57.55
- XOMA N/A
- EPS
- IDR 0.64
- XOMA N/A
- Revenue
- IDR $30,496,328.00
- XOMA $44,952,000.00
- Revenue This Year
- IDR $21.91
- XOMA $70.91
- Revenue Next Year
- IDR $5.47
- XOMA $14.00
- P/E Ratio
- IDR $39.96
- XOMA N/A
- Revenue Growth
- IDR 59.64
- XOMA 194.98
- 52 Week Low
- IDR $9.58
- XOMA $18.35
- 52 Week High
- IDR $27.39
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- IDR 71.70
- XOMA 68.22
- Support Level
- IDR $23.11
- XOMA $25.15
- Resistance Level
- IDR $27.39
- XOMA $33.15
- Average True Range (ATR)
- IDR 1.54
- XOMA 1.74
- MACD
- IDR 0.56
- XOMA 0.59
- Stochastic Oscillator
- IDR 83.41
- XOMA 80.37
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.